Novavax’s COVID-19 Vaccine Has an Edge Over Rivals, Says 5-Star Analyst
Proportion of youth with COVID-19 triples in five months: WHO
A Seller’s Market: Site budgeting in the time of COVID-19
Tool could improve success in translating drugs from animal studies to humans
It's A Mad, Mad, Mad, Mad Market
Researchers develop new mouse model for SARS-CoV-2
NIH launches clinical trial to test antibody treatment in hospitalized COVID-19 patients
46% Of Professionals Fear Being Laid Off Due To Coronavirus
Exposure to common cold coronaviruses can teach the immune system to recognize SARS-CoV-2
"Disconnects" Everywhere...
How COVID-19 could impact travel for years to come
Regeneron: Covid-19 Antibody Combo Prevents & Treats Disease In Animals
Global COVID-19 Spread Slowest In 3 Weeks As Deaths Near 700,000: Live Updates
Deciding how and whether to reopen schools is complex -- here's how rocket scientists would develop a plan
The raging competition for medical supplies is not a game, but game theory can help
Goldman Upgrades Merck To Buy, Lifts PT
"No Silver Bullet" - WHO's Tedros Warns COVID-19 Vaccine May Never Be Found
Next big COVID-19 treatment may be manufactured antibodies
COVID-19 Vaccine Could Mean Regular Injections, No Guarantee Of Immunity
2020 Michelson Prizes support groundbreaking research by young scientists
New published study from K-State virologists identifies potential COVID-19 treatment
A Vaccine May Not Be The "Magical Cure" Everyone Anticipates
RSV vaccination of pregnant women could prevent pneumonia in babies
The six strains of SARS-CoV-2
Eli Lilly Kicks Off Covid-19 Antibody Trial In Nursing Home Residents
S&P Futures Jump To Five Month High, Dollar Spikes In Bullish Start To New Month
Lockdowns Imposed In Melbourne, Manila As Global COVID-19 Total Tops 18 Million: Live Updates
So Covid-19 leader BioNTech has a cancer vaccine in development? Yes, and Regeneron just jumped in for the PhII combo study
Immunic Spikes 35% In Pre-Market On Positive Multiple Sclerosis Data
Varian Pops 24% In Pre-Market On $16.4B Buyout Deal; BTIG Sticks To Buy